What Тивикай Treats: Main Uses and Benefits

Тивикай (Tivicay) is generally used as a critical part of combination therapy (Antiretroviral Therapy or ART) for the long-term management of Human Immunodeficiency Virus (HIV) infection. Its use is relevant for managing the increased physiological stress associated with the condition.

Тивикай is used together with other medicines to treat individuals infected with HIV, by reducing the amount of virus in the body and holding off damage to the immune system.

This medication is applied across domains where additional symptomatic support is needed, primarily for conditions involving sustained viral activity, weakened immune function, and the resulting increased risk of serious illnesses. This is relevant for managing the increased physiological stress and potential functional instability associated with the condition.

Therapeutic Benefits

The core benefit is supporting a sustained reduction in the HIV viral load and facilitating the recovery of CD4 cells. This benefit may assist with maintaining functional stability by reducing the impact of viral activity. By strengthening these defenses, Тивикай contributes to improved day-to-day comfort. It is commonly used when symptoms cluster into patterns requiring supportive management, and may assist in managing conditions characterized by periods of heightened symptoms and maintaining symptomatic stability.

---

Quick Fact: Relief for Systemic Imbalance

---

Regulatory References

1. Tivicay | European Medicines Agency (EMA)

Eligibility Map: Who Can and Cannot Use Тивикай

Official regulatory documents define the population eligibility for dolutegravir by establishing absolute prohibitions and specific inclusion criteria based on age, physiological status, and coexisting conditions.

Eligibility scope	Official Regulatory Status
Populations for whom use is contraindicated	Prohibited in patients with a prior hypersensitivity reaction to dolutegravir. Prohibited with the concomitant use of dofetilide due to the risk of serious events.
Age-related eligibility rules	Adults are eligible. For children, use is established for those aged 4 weeks and older and weighing at least 3 kg (dispersible tablet). Use is not established below these thresholds.
Pregnancy and lactation status	Use should be avoided at the time of conception and through the first trimester of pregnancy due to the risk of neural tube defects; an alternative treatment should be considered. Breastfeeding is not recommended due to the potential risk of HIV-1 transmission.
Condition-specific eligibility rules	Use in patients with severe hepatic impairment (Child-Pugh Grade C) is not recommended due to limited data. Monitoring is recommended for patients with underlying Hepatitis B or C co-infection.

Connection to the Overall Eligibility Profile

The regulatory profile strictly dictates who is formally excluded (contraindicated) and who requires specific caution or monitoring (restricted use). These rules establish boundaries for use based on drug-to-drug interactions, patient reaction history, and specific physiological states, ensuring the medicine is prescribed only under officially documented conditions.

Interactions with other medicines and products

Regulatory documents define specific patterns of interaction for Dolutegravir (Тивикай) that require mandatory administration rules or prohibitions with certain co-administered substances.

Interaction Scope and Restrictions

Feature	Official Regulatory Statement
Contraindicated Combination	Co-administration with Dofetilide (an antiarrhythmic agent) is formally contraindicated due to the potential for significantly increased Dofetilide plasma concentrations.
Primary Mechanism Classes	Chelation with polyvalent cations; Inhibition of the renal transporter OCT2; Sensitivity to metabolic enzyme induction (UGT1A1/CYP3A4).
Timing-Separation Rules	Dolutegravir must be administered 2 hours before or 6 hours after certain oral products containing polyvalent cations, such as aluminum/magnesium antacids, sucralfate, or iron/calcium supplements.
Exposure-Altering Agents	Strong inducers of UGT1A1/CYP3A4 (e.g., Rifampin, Efavirenz) significantly decrease dolutegravir exposure and require a documented dose adjustment. Conversely, Atazanavir increases dolutegravir exposure.
Transporter Interaction	Inhibition of OCT2 leads to increased plasma concentrations of co-administered medicines that are OCT2 substrates, such as Metformin.

Interaction Profile Summary

The interaction profile is structured around these pharmacokinetic constraints. The required timing separation mitigates the risk of reduced drug exposure from chelation, while the OCT2 inhibition dictates the contraindication with Dofetilide and necessary monitoring with Metformin. Official labeling specifies required dose adjustments for specific combinations with enzyme inducers to ensure adequate plasma levels are maintained.

Core Action: Blocking Viral Genetic Integration

Тивикай's core mechanism is the specific inhibition of the HIV-1 Integrase enzyme, a viral protein critical for the virus's lifecycle. The drug functions as an Integrase Strand Transfer Inhibitor (INSTI) by binding tightly to the Integrase-DNA complex and arresting the process of viral DNA insertion into the host cell's genome. This molecular interference halts the production of new infectious particles, which is the mechanistic consequence resulting in the reduction of circulating virus.

---

Secondary Modulation and Limitations

Beyond its primary antiviral role, the drug interacts with the host's Organic Cation Transporter 2 (OCT2), a protein in the kidney tubules. By reversibly inhibiting OCT2, the drug reduces the active transport of certain substances, specifically leading to a measurable, non-pathological, increase in serum creatinine levels. This secondary physiological consequence is produced by the drug's affinity for the host transporter. The activity of the mechanism relies on the structural integrity of the Integrase binding site; specific resistance mutations can alter this site, demonstrating the molecular constraint on the inhibitory action.

How to Use Тивикай (Dolutegravir) — Official Administration Guidelines

Тивикай is required to be used in combination with other antiretroviral agents as part of a complete treatment regimen. The official instructions for use are strictly defined by the dose strength, frequency, and relationship to food and supplements.

Administration Scope

Usage Parameter	Official Instructions (Label-Based)
Route of administration	Oral. Both film-coated and dispersible tablets are administered by mouth.
Dosing schedule (Adults)	Standard: 50 mg once daily. Adjusted: 50 mg twice daily is necessary for patients with documented integrase inhibitor resistance or when certain potent enzyme inducers are co-administered.
Timing in relation to meals	Can be taken with or without food. Taking it with food is preferred when treating patients with integrase resistance to optimize drug exposure.
Preparation requirements	Film-coated tablets: Swallow whole. Dispersible tablets (5 mg): Can be swallowed whole or dispersed in a small amount of drinking water. The suspension must be consumed immediately and should not be chewed or crushed.
Age-group rules	Pediatric: Dosing is weight-based and varies by body weight and formulation. Approved for use in children ge 4 weeks old and weighing ge 3 kg. Impairment: No dose adjustment is required for mild-to-severe renal or mild-to-moderate hepatic impairment.
Missed-dose rules	If a dose is missed, it should be taken as soon as possible, provided the next scheduled dose is more than 4 hours away. Otherwise, the missed dose should be skipped.
Special procedural conditions	The medicine must be taken 2 hours before or 6 hours after cation-containing antacids or supplements (e.g., iron, calcium), unless the dose is taken simultaneously with a meal.

Resulting Procedural Structure

Official use dictates that the correct dose and formulation are ingested daily, either once or twice, according to the official dosing schedule defined by the patient's treatment status. Adherence to specific timing rules regarding cation-containing products is required to ensure adequate absorption, establishing a precise administration framework.

Research Evidence / Overview of Studies for Тивикай (Dolutegravir)

---

Evidence for Starting Antiretroviral Therapy (Treatment-Naïve Adults and Adolescents)

The research foundation for using dolutegravir as a first treatment option was studied for several large, controlled studies, which are often called Randomized Controlled Trials (RCTs). These trials research examined the use of dolutegravir in combination with other anti-HIV medicines in adults and in adolescents (aged 12 years and older). Researchers in these trials monitored the participants to track plasma HIV-1 RNA levels and changes in CD4+ cell counts, which are key measures of immune status.

The research describes patterns related to HIV-1 RNA levels and how CD4+ cells evolved in the observed populations over defined time intervals, usually 48 weeks and often extending to two or three years. The evidence base here is generally considered High level, due to the structure of the various large-scale RCTs that examined this use.

---

Evidence for Patients Who Have Previously Received Treatment (Treatment-Experienced)

For patients who are treatment-experienced but INSTI-naïve, studies explored the short-term symptom changes and activity of switching to or initiating a dolutegravir regimen. These studies monitored the achievement or preservation of plasma HIV-1 RNA < 50 copies/mL and CD4+ cell counts over an intermediate period (typically 48 weeks). The studies describe patterns observed in these groups, with evidence quality also generally considered High in this specific context.

---

Evidence for Managing Drug Resistance

Research for highly treatment-experienced patients who have documented resistance to previous integrase inhibitors is a more specialized area. Studies were conducted primarily using open-label, single-arm designs, meaning there was no group receiving a different medicine for comparison. Researchers examined antiviral activity, focusing on whether participants reached plasma HIV-1 RNA < 50 copies/mL at specific time points.

Because these studies monitored a small and highly specific group, evidence is limited by the modest sample sizes and the lack of a head-to-head comparison group. Therefore, the certainty of the findings in this complex scenario remains low to moderate, and results apply only to the populations studied.

Key Studies & References

1. Treatment Emergent Resistance Data for Dolutegravir-Based Regimens in Treatment Naïve Patients (Pooled GEMINI-1/2 data summary)
2. Pharmacokinetic data of dolutegravir in second-line treatment of children living with HIV: results from the CHAPAS4-trial
3. Pediatric Antiretroviral Drug Information – Dolutegravir (Guidance for the Use of Antiretroviral Agents in Pediatric HIV Infection)

Common questions about Тивикай (FAQ)

---

Q: What happens if I miss a dose of Тивикай?

Official instructions indicate that if a dose is missed, the regulatory guidelines state that a patient may take the missed dose as soon as it is remembered, but only if the next scheduled dose is more than 4 hours away. If the next dose is due within 4 hours, the missed dose should be skipped entirely, and the patient should continue with the usual schedule. Maintaining consistent daily dosing is vital for viral control and to help minimize the risk of the virus developing resistance.

---

Q: Does Тивикай need to be taken with food?

Тивикай can generally be taken with or without food. However, regulatory documents state that taking the medicine with food is the preferred option for patients who have documented integrase inhibitor resistance. This is because food helps increase the absorption of the medicine to optimal levels in this specific patient group.

---

Q: Are there known interactions between Тивикай and antacids?

Yes, interactions with antacids are known. Antacids and other products that contain polyvalent cations, such as aluminum or magnesium, can bind to Тивикай in the stomach and reduce the amount of medicine absorbed into the body. To prevent this effect, official regulatory documents describe the need to take Тивикай 2 hours before or 6 hours after taking these cation-containing products.

---

Q: Can I stop taking Тивикай if my lab results improve?

Official information defines the drug's purpose as achieving and sustaining viral suppression. Treatment for HIV, including regimens containing Тивикай, is typically designed as a continuous, long-term therapy to keep the virus suppressed and prevent viral rebound. The consideration of any change to a long-term treatment plan is a medical decision that requires consultation with a healthcare provider.

---

Q: Does Тивикай affect kidney function?

Тивикай can cause an increase in serum creatinine levels, which is a substance measured to check kidney function. This happens because the medicine temporarily inhibits a transport protein in the kidneys (OCT2). Regulatory documents clarify that this increase is a common, expected finding that is generally considered non-pathological, meaning it does not typically indicate actual kidney damage or loss of function.

---

Q: What is the expected viral load result after being on Тивикай for a period of time?

The goal of treatment, as described in clinical trials, is to reach a plasma HIV-1 RNA level below 50 copies/mL. In studies of adults starting treatment for the first time, high rates of this viral suppression were described at time points such as 48 weeks of continuous use as part of a combination regimen.

---

Q: Can I take Тивикай if I have Hepatitis B or C?

Official safety information notes that patients who also have a chronic Hepatitis B or C co-infection may be at an increased risk for worsening or developing liver enzyme elevations while on antiretroviral therapy. For this reason, monitoring of liver function is recommended for co-infected patients.

---

Q: How quickly does Тивикай start working?

The active substance in the medicine is described as being rapidly absorbed into the bloodstream, usually reaching its peak concentration about 2 to 3 hours after taking the tablet. This rapid absorption is the first step in the medicine's mechanism, leading to a documented rapid decline in viral load in the initial weeks of treatment as reported in clinical studies.

---

Q: Are there any long-term effects of taking Тивикай?

As the medicine is intended for long-term management, clinical studies have followed participants for extended periods, sometimes for over three years, to assess its continued safety profile. Specific long-term concerns noted in regulatory safety information include the need for monitoring weight and metabolic parameters and the potential for developing Immune Reconstitution Inflammatory Syndrome (IRIS).

---

Q: Can Тивикай affect my sleep?

Insomnia (difficulty falling or staying asleep) is listed in official documents as a common side effect, potentially affecting up to 1 in 10 individuals. Abnormal dreams are also reported as a common side effect in some official summaries.

---

Q: Is it common to feel dizzy after starting Тивикай?

Yes, regulatory documents list dizziness as a common side effect of Тивикай. This classification means that dizziness may affect up to 1 in 10 individuals who take the medicine.

---

Q: Can Тивикай interact with herbal supplements?

Yes, interactions with certain supplements are possible. Official documents advise that some herbal preparations, such as St. John's wort, can act as strong enzyme inducers. If taken together, they can significantly decrease the level of dolutegravir in the blood, which could reduce the effectiveness of the HIV treatment.

---

Q: Does Тивикай affect weight gain or loss?

Regulatory warnings indicate that an increase in body weight and changes in metabolic measurements, such as blood lipids and glucose, may occur during antiretroviral therapy. Monitoring these metabolic parameters is recommended as part of the overall management plan.

---

Q: Are there known interactions between Тивикай and vitamins?

Yes, specifically with certain types of vitamins and supplements. Any multivitamins with minerals or other oral supplements containing polyvalent cations (such as iron or calcium) should be administered 2 hours before or 6 hours after taking Тивикай. This timing separation can be waived if the supplements are taken at the same time as a meal.

---

Q: Can taking Тивикай cause changes in mood?

Official safety profiles document side effects that fall under the category of Psychiatric disorders. These reports include common effects like abnormal dreams and documented instances of depression. Rarer, more severe effects, such as suicidal ideation and suicide attempts, have also been reported, particularly in patients with a prior history of mental health issues.

---

Q: Why is it important to take Тивикай every day?

Consistent daily dosing is required because adherence to the administration schedule helps maintain sufficient drug levels in the bloodstream. This consistent level is essential for sustaining viral suppression and for minimizing the risk of the HIV virus developing resistance to the medicine, which could jeopardize the success of the treatment.

---

Q: What is the risk of resistance developing to Тивикай?

Based on clinical data, dolutegravir is described as having a high genetic barrier to resistance compared to certain other integrase inhibitors. This means the medicine is less likely to lead to resistance mutations, particularly when used to treat patients who have not previously taken this class of medicine.

---

Q: Is Тивикай a first-line treatment for HIV?

The medicine is positioned as a key component in HIV treatment. Global treatment guidelines from bodies like the WHO and NIH frequently describe dolutegravir as a preferred or recommended initial antiretroviral treatment for most people with HIV, in combination with other antiretrovirals.

---

Q: Are the side effects of Тивикай the same for everyone?

No. Official safety documents use frequency categories like 'common,' 'uncommon,' and 'rare' to describe side effects observed in clinical trials, indicating that the adverse reactions vary from person to person. Only a subset of people will experience the reported side effects.

---

Q: What happens if I accidentally take two doses of Тивикай?

Regulatory documents state that experience with an accidental overdosage is limited. No specific symptoms were identified in a single-dose study of up to 2000 mg. Overdose is generally managed with supportive care, and continuous monitoring of vital signs is advised.

---

Q: Does Тивикай interact with common blood pressure medications?

Yes, a severe and essential drug interaction is documented. The use of Тивикай with the antiarrhythmic (heart rhythm) medication dofetilide is contraindicated (absolutely prohibited) due to the risk of serious and life-threatening adverse events. The official product information advises that a patient’s prescribing physician be informed of any heart rhythm or blood pressure medication use.

---

Q: Does Тивикай interact with birth control pills?

Clinical studies specifically examined this interaction and determined that dolutegravir does not significantly affect the concentrations of the hormone components (e.g., norgestimate or ethinyl estradiol) found in oral contraceptive pills. Therefore, no dose adjustment or change in contraception method is required based on this interaction.

---

Q: Are there any common reasons why a person might switch from another drug to Тивикай?

Clinical studies have investigated switching to a dolutegravir regimen based on its characteristics, such as its described high barrier to resistance and its efficacy in maintaining viral suppression in certain treatment-experienced populations who may have experienced challenges with previous therapies.

---

Q: Why is my doctor asking about my other medications before starting Тивикай?

A comprehensive medication review is required because Тивикай has several known drug interactions. These interactions must be managed to prevent two outcomes: either the effectiveness of Тивикай is reduced (e.g., by antacids or certain supplements) or the concentration of your other medicines is increased, leading to a potential risk of toxicity (e.g., Dofetilide, Metformin).

---

Q: Can older adults use Тивикай?

Тивикай is approved for use in adults. However, regulatory documents specifically note that there is limited clinical data available on the use of the medicine in patients aged 65 years and older, and for this reason, caution is generally advised in this population.

---

Q: Is there a maximum time someone can take Тивикай?

There is no specified maximum duration for treatment. Тивикай is designed for the long-term management of chronic HIV infection. Clinical studies have provided data demonstrating its long-term safety and efficacy profile over periods exceeding three years.

---

Q: Does the time of day I take Тивикай matter?

The medicine is generally prescribed for once-daily dosing. While it can be taken with or without food, the most important factor is taking it at a consistent time every day. This adherence is necessary to maintain steady, effective drug levels in the bloodstream.

---

Q: Is it safe to drive while taking Тивикай?

Official information advises patients to be aware that side effects such as dizziness and fatigue have been reported. These symptoms may affect your ability to drive or operate machinery, and it is recommended to assess your personal response before performing these activities.

---

Q: What are the typical initial side effects when first starting Тивикай?

The most frequently reported side effects in patients starting the medicine in clinical trials included diarrhea, nausea, and headache. More severe reactions, such as a hypersensitivity reaction (which can involve rash, fever, and organ dysfunction), typically occur within the initial weeks or months of treatment.

---

Q: Is Тивикай available as a single pill combination?

Yes. While the medicine (dolutegravir) is available as a single-agent tablet, it is also available in several fixed-dose combination tablets. These pills combine dolutegravir with other antiretroviral agents (e.g., lamivudine, abacavir) into one single pill for daily use as part of a complete regimen.

How to Store and Dispose of Tivicay (Dolutegravir)

Storage Requirements

Tivicay (dolutegravir) tablets must be stored at controlled room temperature, specifically between 68 F and 77 F (20 C and 25 C). The dispersible tablets (Tivicay PD) should be stored below 86 F (30 C). The medicine must be kept in the original bottle with the cap tightly closed to ensure protection from moisture. It is required that the desiccant packet is not removed from the bottle. To ensure safety, Tivicay must be kept out of the sight and reach of children, and the medicine should not be frozen.

Disposal Instructions

Expired or unused Tivicay must be properly disposed of. Do not throw the tablets into household waste or flush them down a toilet unless specifically instructed to do so by a regulated disposal program. Unneeded medicine should be discarded according to official government guidelines or local regulations for safe medicine disposal.